BERKELEY, Calif., Mar 04, 2009 (BUSINESS WIRE) -- Dynavax Technologies (Nasdaq:DVAX) today announced the appointment of J. Tyler Martin, M.D. as Chief Medical Officer. Dr. Martin will manage Dynavax's clinical affairs, including the development of Dynavax's three current clinical-stage product candidates and three preclinical candidates, which are expected to enter clinical development within the next year.
"Tyler's experience in infectious diseases and his demonstrated record of driving products through clinical development to support regulatory and commercial success will be instrumental as we advance our pipeline of products," said Dino Dina, M.D., President and Chief Executive Officer.
Dr. Martin has close to 20 years of experience in the biotechnology industry and has led development activities to support Investigational New Drug (IND) Applications, New Drug Applications (NDAs), and marketed drugs. Most recently, Dr. Martin was President of Humabs LCC, and before that Vice President, Development at Chiron. In his total of 7 years at Chiron, Dr. Martin led the team responsible for the development of the novel vaccine adjuvant MF59, the first vaccine adjuvant licensed by regulatory agencies since alum, and approved as FLUAD influenza vaccine in Europe. He has also held senior development and research positions at Sangamo, Inc., Valentis, Inc. and SyStemix/GTI. Dr. Martin received a B.S. in Chemistry and an M.D. from the University of Nebraska. He completed his fellowship in pediatric infectious diseases and molecular microbiology at Washington University in St. Louis, Missouri.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of novel Toll-like Receptor (TLR) based product candidates. Based on Dynavax's proprietary technologies, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax has partnerships with leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca AB, and Novartis as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. For more information visit www.dynavax.com.
SOURCE: Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
Copyright Business Wire 2009